Clinical efficacy of intravitreal anti-VEGF drugs has been widely demonstrated in several
angiogenesis-driven eye diseases including diabetic macular edema and the neovascular …

Drugs that prevent the binding of VEGF to its trans-membrane cognate receptors have
revolutionized the treatment of the most important chorioretinal vascular disorders: exudative …

The treatment of ocular neovascular diseases is being revolutionized by intravitreal
therapies targeting vascular endothelial growth factor (VEGF). Two agents are approved for …

Background While randomized controlled trials (RCTs) are based on strict
inclusion/exclusion criteria, non-interventional studies (NISs) might provide additional …

Vascular endothelial growth factor (VEGF) plays an important role in both physiologic and
pathologic angiogenesis and contributes to increased permeability across both the blood …

Anti-vascular endothelial growth factor (VEGF) therapy has revolutionised the treatment of
retinal disease, and appears to be very safe. Nevertheless, there are several lines of …

Introduction: The review aims to discuss effects of vitrectomy on pharmacokinetics of anti-
vascular endothelial growth factor (anti-VEGF) agents, and attempt to provide treatment …

Background Vascular endothelial growth factor (VEGF) plays an important role in many
diseases of the posterior pole that are characterized by macular edema and/or intraocular …

Abstract Antagonists of Vascular Endothelial Growth Factor (Anti-VEGF) are widely
administered by intravitreal injection for the treatment of ocular pathologies such as Age …

Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and
ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic …